Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tanja Fehm

Showing results (291-300 of 371) with videos related to

Pageof 38
Sort By:
Breast Care (Basel, Switzerland)|June 1, 2023
Prevalence of Pathogenic Germline Variants in Women with Non-Familial Unilateral Triple-Negative Breast CancerKerstin Rhiem, Silke Zachariae, Anke Waha, et al.
Oncology Research and Treatment|March 1, 2018
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-StudyFabienne Schochter, Brigitte Rack, Marie Tzschaschel, et al.
The New England Journal of Medicine|January 27, 2012
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancerGunter von Minckwitz, Holger Eidtmann, Mahdi Rezai, et al.
JAMA Oncology|June 24, 2021
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical TrialThomas W P Friedl, Tanja Fehm, Volkmar Müller, et al.
Oncotarget|November 5, 2017
Clinical validation of genetic variants associated with <i>in vitro</i> chemotherapy-related lymphoblastoid cell toxicityPeter A Fasching, Lothar Häberle, Brigitte Rack, et al.
British Journal of Cancer|February 24, 2023
Comparative analysis of EpCAM high-expressing and low-expressing circulating tumour cells with regard to their clonal relationship and clinical valueAndré Franken, Annika Kraemer, Alicia Sicking, et al.
NPJ Breast Cancer|May 14, 2025
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantificationKristin Galas, Moritz Gleitsmann, Julia Rey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical TrialsPaul Jank, Thomas Karn, Marion van Mackelenbergh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Circulating tumor cells in patients with breast cancer dormancySongdong Meng, Debasish Tripathy, Eugene P Frenkel, et al.
Cancer Discovery|February 27, 2015
Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic Acid-induced 2Stefan Werner, Benedikt Brors, Julia Eick, et al.
Pageof 38

Showing results (291-300 of 371) with videos related to

Sort By:
Pageof 38
Breast Care (Basel, Switzerland)|June 1, 2023
Prevalence of Pathogenic Germline Variants in Women with Non-Familial Unilateral Triple-Negative Breast CancerKerstin Rhiem, Silke Zachariae, Anke Waha, et al.
Oncology Research and Treatment|March 1, 2018
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-StudyFabienne Schochter, Brigitte Rack, Marie Tzschaschel, et al.
The New England Journal of Medicine|January 27, 2012
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancerGunter von Minckwitz, Holger Eidtmann, Mahdi Rezai, et al.
JAMA Oncology|June 24, 2021
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical TrialThomas W P Friedl, Tanja Fehm, Volkmar Müller, et al.
Oncotarget|November 5, 2017
Clinical validation of genetic variants associated with <i>in vitro</i> chemotherapy-related lymphoblastoid cell toxicityPeter A Fasching, Lothar Häberle, Brigitte Rack, et al.
British Journal of Cancer|February 24, 2023
Comparative analysis of EpCAM high-expressing and low-expressing circulating tumour cells with regard to their clonal relationship and clinical valueAndré Franken, Annika Kraemer, Alicia Sicking, et al.
NPJ Breast Cancer|May 14, 2025
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantificationKristin Galas, Moritz Gleitsmann, Julia Rey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical TrialsPaul Jank, Thomas Karn, Marion van Mackelenbergh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Circulating tumor cells in patients with breast cancer dormancySongdong Meng, Debasish Tripathy, Eugene P Frenkel, et al.
Cancer Discovery|February 27, 2015
Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic Acid-induced 2Stefan Werner, Benedikt Brors, Julia Eick, et al.
Pageof 38